Format

Send to

Choose Destination
Endocr Rev. 2018 Oct 1;39(5):629-663. doi: 10.1210/er.2017-00191.

Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms.

Author information

1
Translational Research Institute for Metabolism and Diabetes, Florida Hospital, Orlando, Florida.
2
Department of Pediatrics, School of Medicine, University of Colorado Denver, Aurora, Colorado.
3
Barbara Davis Center for Diabetes, Aurora, Colorado.
4
Division of Pediatric Endocrinology, Department of Pediatrics, Stanford University, Stanford, California.
5
Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
6
Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

Abstract

There has been an alarming increase in the prevalence of obesity in people with type 1 diabetes in recent years. Although obesity has long been recognized as a major risk factor for the development of type 2 diabetes and a catalyst for complications, much less is known about the role of obesity in the initiation and pathogenesis of type 1 diabetes. Emerging evidence suggests that obesity contributes to insulin resistance, dyslipidemia, and cardiometabolic complications in type 1 diabetes. Unique therapeutic strategies may be required to address these comorbidities within the context of intensive insulin therapy, which promotes weight gain. There is an urgent need for clinical guidelines for the prevention and management of obesity in type 1 diabetes. The development of these recommendations will require a transdisciplinary research strategy addressing metabolism, molecular mechanisms, lifestyle, neuropsychology, and novel therapeutics. In this review, the prevalence, clinical impact, energy balance physiology, and potential mechanisms of obesity in type 1 diabetes are described, with a special focus on the substantial gaps in knowledge in this field. Our goal is to provide a framework for the evidence base needed to develop type 1 diabetes-specific weight management recommendations that account for the competing outcomes of glycemic control and weight management.

PMID:
30060120
DOI:
10.1210/er.2017-00191
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center